Selvedge Venture

MultiOmic Health is an AI-enabled drug discovery (AIDD) start-up focused on metabolic syndrome-related diseases. It partners with carefully selected healthcare providers to source and analyse de-identified patient data and bio-samples. MultiOmic’s MOHSAIC® platform combines integrated multi-omics analysis and computational systems biology modelling with targeted wet laboratory experiments to originate novel precision therapeutic concepts that MultiOmic commercialises via partnerships with established biopharma companies.

Oxford Medical Products is developing a safe, effective and affordable breakthrough technology for weight loss that uses a self-expanding capsule which occupies space in the stomach, reducing hunger and leading to significant weight loss. Led by a team of scientists, medical professionals, and entrepreneurs who have come together to solve one of the world’s toughest and most urgent medical challenges.

MultiOmic Health is an AI-enabled drug discovery (AIDD) start-up focused on metabolic syndrome-related diseases. It partners with carefully selected healthcare providers to source and analyse de-identified patient data and bio-samples. MultiOmic’s MOHSAIC® platform combines integrated multi-omics analysis and computational systems biology modelling with targeted wet laboratory experiments to originate novel precision therapeutic concepts that MultiOmic commercialises via partnerships with established biopharma companies.

Healthcare demand is rapidly outpacing capacity, the only way to solve this is early detection & prevention. We are building a Clinical Co-pilot that supports clinicians identify patient health changes earlier. We do this by combining healthcare data and translating it into powerful insights that support clinical decision-making (SaMD's :-). Long term vision is to build a human digital twin that understands everyone's health and informs clinicians (via the Clinical Co-pilot) about your health changes. Our secret sauce is a multimodal generative AI platform that translates any type of data streams into clinical insights and easily integrates into clinical workflows and IT systems.

Kytopen is a developer of a cell therapy platform designed for non-viral delivery of molecules into hard-to-transfect immune cells. The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster and cheaper through an automated cell engineering platform, enabling researchers to find new discoveries in biology that will lead to cost effective cell and gene therapies.

Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.

Yuri designs and manufactures a broad range of hardware for the aviation and aerospace industry. Their services include growing cell cultures in 3D, modeling human diseases, analyzing proteins and molecules, synthetic biology, studying plant biology, and nanofluidics.

Oxford Medical Products is developing a safe, effective and affordable breakthrough technology for weight loss that uses a self-expanding capsule which occupies space in the stomach, reducing hunger and leading to significant weight loss. Led by a team of scientists, medical professionals, and entrepreneurs who have come together to solve one of the world’s toughest and most urgent medical challenges.

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well as safe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.

PharmaCCX operates a market access platform with a simple and configurable infrastructure for planning, negotiating, and managing deals. The company software increases the capacity of market access teams at pharma and payers to plan, execute and administer innovative payment models